Abstract 1664P
Background
Despite important implications for patient outcomes, psycho-oncology care (POC) remains underappreciated in low-middle income countries like India. Screening in our patient population revealed high distress levels, among both patients/caregivers and emphasized barriers in accessing mental health care. Our study tests a model of care which proposes early integration of POC in a clinical cancer care setting.
Methods
A multidisciplinary team of ten healthcare professionals, including oncologists, psychologists, oncology nurses and social workers, developed the proposed model. The key components and interventions were: (1) linking counsellor consultation with first patient registration (2) co-counselling of patients and caregivers pre, during and post treatment (3) accessibility of psychologists in inpatient departments through joint ward rounds with treating clinician.
Results
Between Dec 2023 to Mar 2024, 1674 patients reported to Radiation Oncology OPD and 265 had inpatient admissions. The implementation of this model resulted in 31.9% increase in psychological counsellor consultations for outpatients (5.4% to 37.3%), and 82.6% increase for inpatients (12.2% to 94.8%). It also showed 62.68% increase in co-counselling (16.6% to 79.46%). Counsellors flagged off important issues like fear of recurrence or infertility, intimacy issues and reluctance to continuing therapy which patients were hesitant in sharing with the treating physician. Patient reported satisfaction levels evaluated using the OUT-PATSAT35 questionnaire also increased from 62% to 75%.
Conclusions
This model highlights simple ways to prioritise accessibility to mental healthcare in resource limited settings, without adding to the physician work burden and resulting in positive patient outcomes. Increased counsellor accessibility could also be attributed to employing more manpower (3 counsellors versus 1 prior to the study). Despite advising counselling at first contact, not all patients reported for it highlighting a significant barrier to mental therapy. Longer follow up is warranted to evaluate this model’s effectiveness and sustainability.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
N.Bisht.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1617P - Multi-gene copy number variation risk-score for prediction of survival and therapy response outcome in treatment-naïve metastatic castrate resistant prostate cancer
Presenter: Manish Kohli
Session: Poster session 11
1618P - Clinical prognostic factors within the high volume subgroup of metastatic hormone sensitive prostate cancer (mHSPC) in ENZAMET (ANZUP 1304)
Presenter: Anis Hamid
Session: Poster session 11
1619P - Efficacy of carboplatin in patients with metastatic castration-resistant prostate cancer: Results from the biomarker-driven, randomised, outcome-adaptive ProBio trial
Presenter: Anna Kristiansen
Session: Poster session 11
1620P - Inherited variants in SRD5A genes and response to hormonal therapy in prostate cancer (SWOG S1216)
Presenter: Sue Ingles
Session: Poster session 11
Resources:
Abstract
1621P - Validation of a digital pathology-based multimodal artificial intelligence (MMAI) prostate biopsy biomarker in a prospective, real-world Swedish prostate cancer (PCa) cohort treated with radical prostatectomy
Presenter: Anders Bjartell
Session: Poster session 11
1622P - A phase II study of the first-in-class oral innate immune activator BXCL701 with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC): Long-term follow-up
Presenter: Rahul Aggarwal
Session: Poster session 11
1623P - Prognostic value of circulating tumour DNA fraction in metastatic castration-resistant prostate cancer: Insights from the ProBio trial
Presenter: Alessio Crippa
Session: Poster session 11
1624P - Total and regional changes in body composition in metastatic hormone-sensitive prostate cancer (mHSPC) patients randomized to receive androgen deprivation + enzalutamide +/- zoledronic acid: The BonEnza study
Presenter: Martina Buffoni
Session: Poster session 11
1625P - Fuzuloparib combined with abiraterone in the neoadjuvant treatment of localised high-risk prostate cancer (FAST-PC): A single-arm phase II study
Presenter: Yao Zhu
Session: Poster session 11